All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 19, 2022
Home » Blogs » BioWorld MedTech Perspectives » A really bad idea: FDA conducting CE research

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

A really bad idea: FDA conducting CE research

Oct. 6, 2011
By Mark McCarty
No Comments

The question of whether FDA should shoulder the burden of comparative effectiveness research crops up from time to time, but there is more faith in the appropriateness of that notion than I believe is warranted. I only bring this up because Steve Grossman of the Alliance for a Stronger FDA (Washington) raised the issue recently at the Gooznews blog. So let's take a quick look at this issue and examine the question of not just whether FDA is sourced to do this, but whether it should even consider such a task.

As for resources, this is a no-brainer. While the folks at the Centers for Medicare & Medicaid Services might disagree, the prevailing view seems to be that FDA suffers from the most serious mismatch in terms of resources and tasks, a view that is far from a novelty. This alone ought to quash any further such discussion, but apparently is not.

Another point to be made here is that comparative effectiveness is a very different animal than safety and efficacy, and I just don't see that FDA as it is currently constituted is prepared to deal with CE considerations. After all, the point of CE is not to discern which treatment is superior (or non-inferior), but for which patients is which treatment superior. My impression is that the base of data for making such evaluations is not particularly well built out as yet. In the case of the highly iterative therapeutic medical device, the data are obsolete by the time you have them anyway.

This question of data obsolescence does not apply to all devices, that's true. It's also true that comparing medical management to a device type may be illuminating, but a different coating on a drug-eluting stent or a different algorithm in an implantable defibrillator can quickly render a comparison irrelevant.

I'd also hasten to point out that those who believe FDA should handle CE are doing a nice job of ignoring the fact that the taxpayer is already financing two entities whose charge is just this, namely the Agency for Healthcare Research and Quality and the Federal Coordinating Council for Comparative Effectiveness Research. Really, is there any need for FDA to get involved at all?

And finally, one must ask how would FDA obtain the data needed to conduct CE research. The short answer? Clinical trials financed by industry. No longer would it suffice to demonstrate safety and efficacy compared to the current standard of care. Now you have to enroll even more. If you are a big fan of device flight, you'll love this idea. What better way to drive more device makers out of the U.S.?

So I'd like to make a request of everyone inside and around the Beltway. Please, enough of this business of having FDA conduct CE research. It's a lousy idea any way you slice it and even if the agency could do it, it'd be redundant. May we now finally lay this idea to rest?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 19, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 19, 2022.
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
  • TPOXX

    Siga leads monkeypox antiviral research, amid lack of interest from big pharma

    BioWorld
    After declarations from the World Health Organization and the U.S. government that monkeypox is a public health emergency, attention is turning to the pharma...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing